HighTower Advisors’s Immuneering IMRX Stock Holding History

HighTower Advisors’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$716K	Buy	143,486 +12,200	+9%	+$61.7K	﹤0.01%	2465
2026 Q1	$692K	Buy	131,286 +19,962	+18%	+$102K	﹤0.01%	2450
2025 Q4	$733K	Sell	111,324 -21,135	-16%	-$136K	﹤0.01%	2338
2025 Q3	$927K	Sell	132,459 -3,501	-3%	-$18.2K	﹤0.01%	2163
2025 Q2	$458K	Buy	135,960 +52,000	+62%	+$89.1K	﹤0.01%	2598
2025 Q1	$128K	Buy	83,960 +12,600	+18%	+$22.9K	﹤0.01%	3310
2024 Q4	$157K	Buy	71,360 +18,000	+34%	+$37.3K	﹤0.01%	3264
2024 Q3	$132K	Buy	53,360 +9,400	+21%	+$13.7K	﹤0.01%	3247
2024 Q2	$57K	Buy	+43,960	New	+$72.3K	﹤0.01%	3287
2024 Q1	–	Sell	-23,960	Closed	-$176K	–	3817
2023 Q4	$176K	Hold	23,960	–	–	﹤0.01%	3051
2023 Q3	$184K	Buy	+23,960	New	+$220K	﹤0.01%	2942

Other funds holding IMRX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

HighTower Advisors's IMRX Position: Q2 2026 in Review

HighTower Advisors increased its Immuneering (IMRX) stake by 9.3% in Q2 2026, buying an estimated $61.7K and bringing the position to 143,486 shares worth $716K. The position accounts for ﹤0.01% of the portfolio, ranked #2465.

HighTower Advisors first reported a position in IMRX in Q3 2023 and has held it in 11 quarters since. The position peaked at $927K in Q3 2025. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

HighTower Advisors held 143,486 shares of Immuneering worth $716K as of Q2 2026.
HighTower Advisors bought 12,200 Immuneering shares in Q2 2026, an estimated $61.7K.
Immuneering made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2465 holding.
HighTower Advisors first reported a position in Immuneering in Q3 2023 and has held it in 11 quarters since.
HighTower Advisors's Immuneering position peaked at $927K in Q3 2025.
112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.